Department of Disease Control and Prevention, School of Medicine, Eden University, Lusaka, Zambia.
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Pan Afr Med J. 2023 Jun 22;45:98. doi: 10.11604/pamj.2023.45.98.37017. eCollection 2023.
Antiretroviral treatment failure has emerged as a challenge in the management of pediatric human immunodeficiency virus (HIV) patients, especially in resource-limited countries despite accessibility to Highly Active Antiretroviral Therapy (HAART). A systematic review and meta-analysis was conducted to synthesize virological failure (VF) prevalence and ascertain its predictors in children in sub-Saharan Africa. An electronic database search strategy was conducted from January to September 2021 on PubMed, EMBASE, SCOPUS, HINARI, and CINAHL. Further, manual searching was conducted on non-indexed journals. Utilizing the JASP© version 0.17.2 (2023) statistical software, a meta-analysis of pooled prevalence of VF was estimated using the standardized mean differences. Further, selection models were used to assess the risk of bias and heterogeneity. The pooled odds ratios were estimated for the respective studies reporting on predictors of VF. The overall pooled estimate of the prevalence of VF in sub-Saharan Africa among the sampled population was 29% (95% CI: 27.0-32.0; p<0.001). Predictors of VF were drug resistance (OR: 1.68; 95% CI: 0.88-2.49; p < 0.001), poor adherence (OR: 5.35; 95% CI: 5.26-5.45; p < 0.001), nevirapine (NVP)-based regimen (OR: 5.11; 95% CI: 4.66-5.56; p < 0.001), non-usage of cotrimoxazole prophylaxis (OR: 4.30; 95% CI: 4.13-4.47; p < 0.001), higher viral load at the initiation of antiretroviral therapy (ART) (OR: 244.32; 95% CI: 244.2-244.47; p <0.001), exposure to the prevention of mother to child transmission (PMTCT) (OR: 8.02; 95%CI: 7.58-8.46; p < 0.001), increased age/older age (OR: 3.37; 95% CI: 2.70-4.04; p < 0.001), advanced World Health Organization (WHO) stage (OR: 6.57; 95% CI: 6.17-6.98; p < 0.001), not having both parents as primary caregivers (OR: 3.01; 95% CI: 2.50-3.53; p < 0.001), and tuberclosis (TB) treatment (OR: 4.22; 95% CI: 3.68-4.76; p <0.001). The mean VF prevalence documented is at variance with studies in other developing countries outside the sub-Saharan region. The high prevalence of HIV cases contrasting with the limited expertise in the management of pediatric ART patients could explain this variance.
抗逆转录病毒治疗失败已成为儿科人类免疫缺陷病毒 (HIV) 患者管理中的一个挑战,尽管在资源有限的国家也可以获得高效抗逆转录病毒治疗 (HAART),但情况依然如此。本研究进行了一项系统评价和荟萃分析,旨在综合评估撒哈拉以南非洲地区儿童中病毒学失败 (VF) 的流行情况,并确定其预测因素。从 2021 年 1 月到 9 月,我们在 PubMed、EMBASE、SCOPUS、HINARI 和 CINAHL 等电子数据库中进行了检索策略,并在非索引期刊上进行了手动检索。利用 JASP©版本 0.17.2(2023 年)统计软件,使用标准化均数差值估计了 VF 合并患病率的荟萃分析。此外,还使用选择模型评估了偏倚和异质性的风险。对报告 VF 预测因素的各自研究进行了汇总比值比的估计。在抽样人群中,撒哈拉以南非洲地区 VF 的总体合并患病率为 29%(95%CI:27.0-32.0;p<0.001)。VF 的预测因素包括耐药性(OR:1.68;95%CI:0.88-2.49;p < 0.001)、治疗依从性差(OR:5.35;95%CI:5.26-5.45;p < 0.001)、基于奈韦拉平 (NVP) 的方案(OR:5.11;95%CI:4.66-5.56;p < 0.001)、未使用复方磺胺甲噁唑预防(OR:4.30;95%CI:4.13-4.47;p < 0.001)、抗逆转录病毒治疗 (ART) 开始时病毒载量较高(OR:244.32;95%CI:244.2-244.47;p < 0.001)、接触母婴传播预防 (PMTCT)(OR:8.02;95%CI:7.58-8.46;p < 0.001)、年龄较大/年龄较大(OR:3.37;95%CI:2.70-4.04;p < 0.001)、较高的世界卫生组织 (WHO) 阶段(OR:6.57;95%CI:6.17-6.98;p < 0.001)、没有父母双方作为主要照顾者(OR:3.01;95%CI:2.50-3.53;p < 0.001)和结核病 (TB) 治疗(OR:4.22;95%CI:3.68-4.76;p <0.001)。记录的平均 VF 患病率与撒哈拉以南非洲地区以外其他发展中国家的研究存在差异。HIV 病例高发与儿科 ART 患者管理方面专业知识有限的情况形成鲜明对比,这可能解释了这种差异。